Fujian Akeylink Biotechnology Co., Ltd.
10
2
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
10%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment
Role: lead
A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B
Role: lead
Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets
Role: lead
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function
Role: lead
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function
Role: lead
Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants
Role: lead
Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants
Role: lead
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG171 Tablets
Role: lead
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG121 Tablets
Role: lead
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
Role: lead
All 10 trials loaded